Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of DXC008 in prostate cancer and other solid tumors
ChiCTR2500100610Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of DXC008 in prostate cancer (PCa), Ewing sarcoma and Nonhematologic neoplasms, sponsored by Peking University First Hospital. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
DXC008
03
Conditions
prostate cancer (PCa)Ewing sarcomaNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500100610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100610.